Bristol-Myers Squibb (BMY) volatility flat at 20 into positive clinical results
Get Alerts BMY Hot Sheet
Price: $54.23 +1.84%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.4%
Revenue Growth %: +1.4%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.4%
Revenue Growth %: +1.4%
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) is recently up 7.2% in pre-open trading following promising clinical results from stroke-preventing Eliquis. Deutsche Bank reiterated their Buy rating and $31.50 price target on BMY. Overall option implied volatility of 20 is near its six-month average according to Track Data.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
- iShares Silver Trust (SLV) April calls active
- Russell 2000 (RUT) call put ratio 1 call to 1.7 puts into Core PCE report and Jerome Powell speech
Create E-mail Alert Related Categories
OptionsRelated Entities
Deutsche Bank, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!